electroCore (ECOR) vs Sera Prognostics (SERA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
electroCore (ECOR) has outperformed Sera Prognostics (SERA) over the past year, gaining 84.7% versus a loss of 35.9%. Over five years, ECOR leads with a -36.4% price change compared with -81.4% for SERA. electroCore is the larger company by market cap ($87.4 million vs $79.3 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ECOR | SERA |
|---|---|---|
| Share price | $9.69 | $2.01 |
| Market cap | $87.36M | $79.29M |
| 1-day change | +1.89% | -0.50% |
| YTD return | +112.04% | -31.53% |
| 1-year return | +84.66% | -35.87% |
| 5-year return | -36.41% | -81.38% |
| EPS (TTM) | $-1.65 | $-0.67 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $12.70 | $3.95 |
| 52-week low | $4.41 | $1.56 |
| Distance from 52-week high | -23.70% | -49.11% |
| Analyst consensus | none | none |
| Avg. price target upside | +97.83% | +173.63% |
| Average volume | 80.51K | 27.84K |
| Shares outstanding | 9.02M | 38.48M |
| Employees | 83 | 71 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Medical Specialities |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ECOR has outperformed SERA by 120.5 percentage points over the past year.
About electroCore
ECOR stock →electroCore, Inc., a bioelectronic technology medicine and general wellness company, provides non-invasive vagus nerve stimulation (nVNS) technology platform in the United States, the United Kingdom, and internationally. The company develops gammaCore, a prescription only handheld device intended for regular or intermittent use for the acute treatment of pain associated with migraine and episodic cluster headache, as well as for the treatment of hemicrania continua and paroxysmal hemicrania.
Health Care · Biotechnology: Electromedical & Electrotherapeutic Apparatus · 83 employees
About Sera Prognostics
SERA stock →Sera Prognostics, Inc., a women's health company, discovers, develops, and commercializes blood-based biomarker tests, and predictive analytic products and services in the United States. The company develops the PreTRM test, a non-invasive blood test given to a pregnant woman, carrying a single fetus, during weeks 18 through 20 of gestation.
Health Care · Medical Specialities · 71 employees
ECOR vs SERA FAQ
Which is bigger, electroCore or Sera Prognostics?
electroCore (ECOR) is larger, with a market capitalization of $87.36M compared with $79.29M for Sera Prognostics (SERA).
Which stock has performed better over the past year, ECOR or SERA?
ECOR returned +84.66% over the past 12 months, compared with -35.87% for SERA (price return, excluding dividends). Past performance does not predict future results.
Are electroCore and Sera Prognostics in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Electromedical & Electrotherapeutic Apparatus for electroCore and Medical Specialities for Sera Prognostics.